Modulation of vasorelaxant responses to potassium channel openers by basal nitric oxide in the rat isolated superior mesenteric arterial bed.
1. We have used the isolated buffer-perfused mesenteric arterial bed of the rat to assess the modulation of vasorelaxation to potassium channel openers (KCOs) by basal nitric oxide. 2. The dose-response curves to the KCOs, levcromakalim and pinacidil, in preconstricted preparations were significantly shifted to the left in the presence of the nitric oxide synthase inhibitor (100 microM) NG-nitro-L-arginine methyl ester (levcromakalim, ED50 = 4.47 +/- 0.70 nmol vs. 1.73 +/- 0.26 nmol, P < 0.001; pinacidil, ED50 = 16.1 +/- 4.8 nmol vs. 5.43 +/- 1.10 nmol, P < 0.001). The vasorelaxant responses to papaverine, a vasodilator which acts independently of potassium channels was unaffected by NG-nitro-L-arginine methyl ester (L-NAME). 3. Removal of the endothelium, by perfusion with the detergent CHAPS (0.3%), significantly (P < 0.001) increased the potency of levcromakalim as a vasodilator (ED50 4.47 +/- 0.70 nmol vs. 2.59 +/- 0.31 nmol). The subsequent administration of L-NAME following perfusion with CHAPS did not lead to any additional enhancement of responses to levcromakalim. 4. The presence of the non-selective adenosine antagonist, 8-phenyltheophylline (8-PT, 10 microM) significantly (P < 0.001) shifted the dose-response curve to levcromakalim to the left (ED50 4.47 +/- 0.70 nmol vs. 1.11 +/- 0.32 nmol). In the presence of both L-NAME and 8-PT, the dose-response curve to levcromakalim was also significantly (P < 0.01) shifted to the left compared with control (ED50 in the presence of both L-NAME and 8-PT was 0.42 +/- 0.08 nmol). 5. The presence of 8-bromo cyclic GMP (10 microM) reversed the increase potency of levcromakalim, observed following inhibition of nitric oxide synthase (ED50 in the presence of L-NAME was 0.59 +/- 0.01 nmol and in the presence of 8-bromo cyclic GMP plus L-NAME the ED50 was 3.17 +/- 0.80 nmol). However in the absence of L-NAME, the cell permeable analogue of cyclic GMP, 8-bromo cyclic GMP, did not affect the dose-response curve to levcromakalim compared with control (control ED50 value was 4.16 +/- 0.52 nmol vs. 3.85 +/- 1.13 nmol in the presence of 8-bromo cyclic GMP). 6. The present investigation demonstrates that both basal nitric oxide and adenosine modulate vasorelaxation to the KCOs levcromakalim and pinacidil. The modulatory effect of nitric oxide may be mediated via cyclic GMP.
McCulloch
A I
AI
Department of Physiology and Pharmacology, University of Nottingham Medical School.
Randall
M D
MD
D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology; D019806:Cromakalim; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006146:Guanidines / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D017538:Mesenteric Artery, Superior / Q000187:drug effects* / Q000502:physiology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D009569:Nitric Oxide / Q000037:antagonists & inhibitors*; D009599:Nitroprusside / Q000494:pharmacology; D010208:Papaverine / Q000494:pharmacology; D020110:Pinacidil; D015221:Potassium Channels / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013237:Stereoisomerism; D013806:Theophylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
D001578:Benzopyrans; D006146:Guanidines; D015221:Potassium Channels; D011758:Pyrroles; D014665:Vasodilator Agents; D019806:Cromakalim; D009599:Nitroprusside; C016276:8-bromocyclic GMP; D009569:Nitric Oxide; D020110:Pinacidil; D013806:Theophylline; D010208:Papaverine; C028322:8-phenyltheophylline; D006152:Cyclic GMP; D019331:NG-Nitroarginine Methyl Ester